Skip to Main Content

An Amgen (AMGN) employee violated Danish law by sharing and liking a U.S. press release about a medicine on LinkedIn, but will not be sanctioned, nor is the company being held responsible for the incident, the Danish Medicines Agency has decided. The employee could have faced up to four months in jail and the drug maker might have been liable for a penalty.

The press release in question was issued last August and contained positive study results about the Kyprolis cancer treatment when compared with another medicine called Velcade. And the results indicated that Kyprolis should replace Velcade as the standard of care when a patient relapses with multiple myeloma.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!